Interleukin-2 (IL-2) is a signaling protein produced by the immune system that acts as a growth factor for T cells, the white blood cells responsible for fighting infections and cancer. First identified in the late 1970s by researchers Frank Ruscetti and Robert Gallo, it was originally called “T-cell growth factor” because it allowed scientists to grow T cells in the lab for the first time. IL-2 has since become one of the most studied molecules in immunology, with roles in both revving up immune attacks and, perhaps surprisingly, keeping the immune system in check.
What IL-2 Does in the Immune System
When your body encounters a virus, bacterium, or abnormal cell, certain T cells become activated and begin releasing IL-2. That IL-2 then acts like a broadcast signal, telling nearby immune cells to multiply and gear up for a fight. Its strongest effect is on CD8+ T cells, the “killer” cells that directly destroy infected or cancerous cells. IL-2 promotes their growth and helps them mature into more effective fighters. Interestingly, it has relatively little direct effect on CD4+ “helper” T cells.
But IL-2 plays a second, seemingly contradictory role. It is essential for the survival and function of regulatory T cells (Tregs), a specialized population that prevents the immune system from attacking the body’s own tissues. Tregs depend on IL-2 so heavily that mice engineered to lack IL-2 have almost no Tregs in their bodies and develop severe autoimmune disease. This dual nature, both activating the immune response and maintaining the cells that suppress it, makes IL-2 one of the most nuanced molecules in immunology. In fact, research has shown that the net effect of IL-2 signaling is more often growth-limiting (through Tregs) than growth-promoting.
How IL-2 Sends Its Signal
IL-2 works by binding to a receptor on the surface of T cells. That receptor is made of three protein subunits that fit together like puzzle pieces. The first subunit acts as a catcher, grabbing onto IL-2 and holding it in place. The second and third subunits then join the complex and are the parts that actually transmit the signal into the cell’s interior. Together, the three-part receptor binds IL-2 extremely tightly, roughly a thousand times more strongly than any single subunit could on its own.
Once the complete receptor assembles, it triggers a chain reaction inside the cell. Enzymes attached to the receptor’s inner tail switch on, which in turn activates a transcription factor called STAT5. STAT5 travels to the cell’s nucleus and flips on genes that drive the cell to grow, divide, or carry out its suppressive functions. This signaling cascade also branches into pathways that regulate cell survival and metabolism. The specifics matter because they explain why different cell types respond to IL-2 differently: Tregs display all three receptor subunits at high levels and respond to even tiny amounts of IL-2, while other immune cells need much higher concentrations to get the same signal.
IL-2 as a Cancer Treatment
IL-2 was one of the first immunotherapy drugs. The idea was straightforward: flood the body with IL-2 to supercharge the immune system’s ability to kill tumor cells. The synthetic version, called aldesleukin, was approved by the FDA for metastatic kidney cancer and later for metastatic melanoma in 1998. In both cancers, high-dose IL-2 can produce durable, complete responses in a small percentage of patients, meaning some people see their tumors disappear and stay gone for years.
The treatment protocol is intense. Patients receive IL-2 intravenously every eight hours for up to five days, with a maximum of 14 doses per cycle. A typical course consists of two cycles separated by a rest period of nine to 14 days. The standard dose is 600,000 international units per kilogram of body weight, though some centers use 720,000. Each dose is given as a short infusion over about 15 minutes, and patients are monitored closely in a hospital setting throughout.
Side Effects of High-Dose IL-2
The reason high-dose IL-2 requires such careful monitoring is a phenomenon called vascular leak syndrome. When large amounts of IL-2 circulate through the body, they trigger widespread activation of the cells lining blood vessels. This doesn’t happen because IL-2 acts on those cells directly. Instead, it stimulates immune cells to release a cascade of other inflammatory signals, including tumor necrosis factor and interferon-gamma, which then cause blood vessel walls to become leaky. Fluid seeps out of the bloodstream and into surrounding tissues, leading to swelling, a drop in blood pressure, and in severe cases, organ dysfunction.
This toxicity is the main limitation of high-dose IL-2 therapy. Most patients cannot tolerate the full 14 doses, and treatment teams make dose-by-dose decisions about whether to continue based on how the patient is responding. The side effects are reversible once the drug is stopped, but they make the treatment unsuitable for anyone who isn’t in otherwise good health. This toxicity profile is a major reason researchers have spent decades trying to build a better version of IL-2.
Engineered IL-2 Variants
The core challenge with natural IL-2 is its dual personality. In cancer, you want to activate killer T cells without simultaneously boosting Tregs (which can shield tumors from immune attack). In autoimmune disease, you want the opposite: activate Tregs without stirring up the rest of the immune system. Researchers have responded by engineering modified versions of IL-2 that are biased toward one effect or the other.
Several of these are now in clinical trials. NKTR-214 and ALKS 4230 are designed to preferentially activate killer T cells and natural killer cells while avoiding Tregs, making them candidates for cancer therapy with fewer side effects. MDNA109 was built specifically to maximize antitumor effects while minimizing immune-related toxicity. On the other side of the spectrum, AMG 592 selectively activates Tregs, making it a potential treatment for autoimmune conditions. Some newer approaches fuse IL-2 with other immune-targeting molecules. Combinations that pair IL-2 signaling with PD-1 blockade, for example, aim to expand killer T cells without the simultaneous Treg expansion that can blunt cancer immunotherapy.
Low-Dose IL-2 for Autoimmune Disease
One of the more counterintuitive developments in IL-2 research is giving it in very small doses to treat autoimmune diseases, conditions where the immune system is already overactive. The logic hinges on the fact that Tregs are far more sensitive to IL-2 than other immune cells. At low concentrations, IL-2 selectively expands and activates the Treg population while leaving effector T cells largely unaffected. The result is a net dampening of immune activity.
Early clinical work has tested this approach across a range of autoimmune conditions, and the pattern holds: low-dose IL-2 consistently expands Tregs without activating the effector cells that drive disease. This makes it a fundamentally different strategy from the high-dose regimens used in cancer, even though the molecule is the same. The dose determines whether IL-2 acts as an immune accelerator or an immune brake.